Sol Gel Technologies Ltd (SLGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has a cash flow conversion efficiency ratio of 0.045x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.89 Million) by net assets ($42.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Sol Gel Technologies Ltd balance sheet independence to measure how much of total assets are equity-financed.
Sol Gel Technologies Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Sol Gel Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sol Gel Technologies Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Sol Gel Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sol Gel Technologies Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOLDGROUP MINING INC.
F:55G0
|
0.068x |
|
Chlitina Holding Ltd
TW:4137
|
0.013x |
|
Webzen Inc
KQ:069080
|
0.009x |
|
Cricut Inc
NASDAQ:CRCT
|
0.240x |
|
Hengxin Mobile Business
SHE:300081
|
-0.006x |
|
JINMAO PROPERTY SERVICES
F:TZ0
|
N/A |
|
Companhia Brasileira de Distribuição
SA:PCAR3
|
0.455x |
|
Pacific Smiles Group Ltd
AU:PSQ
|
0.382x |
Annual Cash Flow Conversion Efficiency for Sol Gel Technologies Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Sol Gel Technologies Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Sol Gel Technologies Ltd (SLGL) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $22.81 Million | $322.00K | 0.014x | +102.93% |
| 2024-12-31 | $28.85 Million | $-13.89 Million | -0.481x | -4.93% |
| 2023-12-31 | $38.64 Million | $-17.73 Million | -0.459x | -104.21% |
| 2022-12-31 | $42.21 Million | $-9.48 Million | -0.225x | -62.40% |
| 2021-12-31 | $55.59 Million | $-7.69 Million | -0.138x | +72.13% |
| 2020-12-31 | $50.85 Million | $-25.24 Million | -0.496x | -15.75% |
| 2019-12-31 | $52.47 Million | $-22.50 Million | -0.429x | -16.79% |
| 2018-12-31 | $63.91 Million | $-23.47 Million | -0.367x | -180.33% |
| 2017-12-31 | $-52.70 Million | $-24.09 Million | 0.457x | -22.55% |
| 2016-12-31 | $-31.34 Million | $-18.50 Million | 0.590x | -15.49% |
| 2015-12-31 | $-11.52 Million | $-8.04 Million | 0.698x | -67.11% |
| 2014-12-31 | $-2.27 Million | $-4.83 Million | 2.123x | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more